Plasma-based diagnostics are ideal for detecting a variety of diseases because they offer a
method of detection that is minimally invasive, readily available, and easy to use for …

Pancreatic ductal adenocarcinoma (PDAC) is rapidly becoming one of the leading causes of
cancer-related deaths in the United States, and with its high mortality rate, there is a …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor
prognosis, primarily due to a late diagnosis. Recent studies have focused on identifying non …

Pancreatic ductal adenocarcinoma (PDAC) remains a difficult tumor to diagnose and treat.
To date, PDAC lacks routine screening with no markers available for early detection …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival
rate of< 8%[1–3]. PDAC is characterized by dense desmoplastic stroma, which can …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with an overall
five-year survival rate of 11%. Potential curative resection is possible if the tumor is detected …

Pancreatic ductal adenocarcinoma (PDAC) is considered one of the most aggressive
malignancies and has high mortality and poor survival rates. Therefore, there is an urgent …

Background: Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second
leading cause of cancer-related deaths in the United States by 2030. Most of the PDAC …

Despite the development of several therapeutic options, the prognosis of pancreatic cancer
remains poor. One reason for this is the difficulty of diagnosing the disease at an early stage …

Abstract Background & Aims Pancreatic ductal adenocarcinoma (PDAC) incidence is rising
worldwide, and most patients present with an unresectable disease at initial diagnosis …